Clinical Trial Update: NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating NY-ESO-1 protein with Montanide and CpG 7909 as a cancer vaccine across multiple tumor types; study completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• CPG 7909 (CpG 7909)
• Montanide (Montanide adjuvant)
• NY-ESO-1 protein (NY-ESO-1 recombinant protein)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Tumors | Phase 1 | Status: COMPLETED | Results posted: 2021-11-26